Abstract 5037
Background
Numerous investigations have been focused on the role of CXCR4, CCR2 and CCR5 in solid tumors, including breast cancer. These chemokine receptors make cancer cells move out of the circulation and traffic into organs with high amounts of chemokines, and thus forming metastases. In this connection, the objective of our stady was to investigate CXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features in primary tumor and peripheral blood in breast cancer patients.
Methods
Twenty-three patients with breast cancer, between 29 and 69 years of age, were included in this study. Five-color confocal microscopy was used to investigate tumor cells with stem and/or EMT features, CXCR4, CCR2 and CCR5 expression in primary tumor. Flow cytometry was used to analyze the similar phenotypes of circulating tumor cells (CTC). All patients signed an informed consent for voluntary participation.
Results
In the primary tumor, CXCR4 was expressed on subsets of non-stem and stem-like tumor cells with EMT features. CCR5 was more often expressed by tumor cells with stem and EMT features. The count of such cells in the tumor decreased after neoadjuvant chemotherapy (NACT). CK7+CD45-CD44-CCR2+ and CK7+CD45-CD44-CXCR4+ CTC (without stem features) were detected in breast cancer patients with and without NACT. At the same time, the count of non-stem CXCR4+ CTC was significantly higher in the blood of patients after NACT. CK7+CD45-CD44-N-cadh+CCR5+ CTC (with EMT features) were more frequent in the blood of breast cancer patients after NACT, and its count was significantly higher. It is interesting to note that stem-like CTC didn’t express CCR2 and CCR5. Stem-like CXCR4+ CTC were rarely detected and had no EMT features in patients, regardless of the NACT performance. The count of CCR5+ tumor cells without stem and EMT features correlates with the count of non-stem CCR5+ CTC. The count of CXCR4+ tumor cells with stem and EMT features correlates with the count of non-stem CXCR4+ CTC with EMT features.
Conclusions
Thus, the potency for recruitment into the circulation is found in tumor cells with EMT features, regardless of the stemness status. The study was supported by the Russian Science Foundation (grant 19-75-30016).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1267 - Genetic landscape of KEAP1 and NFE2L2 mutated cancers from the AACR GENIE database
Presenter: Mark Zaki
Session: Poster Display session 1
Resources:
Abstract
878 - β-arrestin1 is involved in the Ras-induced malignant transformation
Presenter: Takashi Shibano
Session: Poster Display session 1
Resources:
Abstract
4143 - Incidence of second cancer among PLWHIV: retrospective observational study of a series of 601 patients in the French CANCERVIH network
Presenter: Jean-Philippe Spano
Session: Poster Display session 1
Resources:
Abstract
5145 - A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: the CUPISCO trial experience
Presenter: Chantal Pauli
Session: Poster Display session 1
Resources:
Abstract
1737 - Incidence and Outcome of chronic lymphocytic leukemia with Deletion 17p: An Indian experience; challenges and opportunities
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
2596 - Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia
Presenter: Jonathan Killian
Session: Poster Display session 1
Resources:
Abstract
1499 - The potential of a novel antiangiogenic VEGFR1-D2 binding peptide in oncology therapeutics
Presenter: Afsaneh Sadre Momtaz
Session: Poster Display session 1
Resources:
Abstract
1775 - First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
Presenter: Mayu Yunokawa
Session: Poster Display session 1
Resources:
Abstract
4584 - First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumors: Dose-optimization cohorts
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract